David A. Siegel Galera Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.5 - $3.42 $1,000 - $1,368	-400 Reduced 3.05%	12,700 $39,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.68 $148 - $268	-100 Reduced 0.76%	13,100 $33,000
Q4 2022 Feb 14, 2023	SELL	$1.34 - $1.78 $1,206 - $1,602	-900 Reduced 6.38%	13,200 $19,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $2.1 $42,320 - $77,280	-36,800 Reduced 72.3%	14,100 $25,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.39 $123,008 - $237,088	-99,200 Reduced 66.09%	50,900 $66,000
Q1 2022 May 16, 2022	BUY	$2.01 - $4.19 $268,737 - $560,203	133,700 Added 815.24%	150,100 $357,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $8.28 $20,828 - $135,792	16,400 New	16,400 $75,000

909K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.07M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.